TransTissue, founded as a spin-off of the University Hospital Charité in February 2000, has been a subsidiary of BioTissue Technologies, Freiburg since September 2001.

With more than 15 years of experience in the field of tissue engineering and regenerative medicine, the scientists and founders of TransTissue have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts and innovative third-generation cell-free cartilage implants.

As a technology company, we focus on inventions and the development of products and treatment strategies in regenerative medicine.